A study of pre- and post-treatment hematologic markers of immune response in patients undergoing radiotherapy for soft tissue sarcoma
These results suggest that hematologic markers could serve as prognostic biomarkers in both pre- and post-treatment settings for STS patients undergoing RT. Future studies can consider using bone V10Gy < 362 cc as a potential cutoff to reduce the risk of increased PLR after RT.
Authors
- Nicholas Peterson (ORCID: https://orcid.org/0000-0003-4157-8119)
- Russell Stitzlein
- Eric Ku (ORCID: https://orcid.org/0000-0002-4335-2116)
- Garrett K. Harada (ORCID: https://orcid.org/0000-0002-7024-3783)
- Warren Chow (ORCID: https://orcid.org/0000-0003-0889-5841)
- Akul Munjal
- Jeremy P. Harris (ORCID: https://orcid.org/0000-0001-7603-0263)
- Charles L. Limoli (ORCID: https://orcid.org/0000-0002-1321-4142)
- Jino Park (ORCID: https://orcid.org/0000-0001-5228-3880)
- Grace Lee
Institutions
- University of California, Irvine (US)
- University of California, Irvine Medical Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-03
- DOI
- https://doi.org/10.3389/fonc.2024.1392705
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- National Institutes of Health
- University of California, Irvine
- National Cancer Institute